OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
09 nov 2007 - 00:39
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus to raise additional funds for the further development of its product pipeline
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today that it plans to raise up to € 25 million in a follow-on financing through a public offering of new shares in the Netherlands and a private placement of new shares with institutional investors in certain other jurisdictions. The offer price will be determined on the basis of a book-building process. The proceeds of the offering will be used primarily for the further development of OctoPlus’ product pipeline, including its lead product Locteron™.
Cowen International Limited and Kempen & Co have been appointed as joint bookrunners and joint global coordinators for the offer, and SNS Securities will act as co-manager (collectively, the “Underwriters”).
The availability of the prospectus and the commencement of the subscription period are expected to be announced on 12 November 2007 by a further press release.
Gerelateerde downloads
Datum laatste update: 27 juli 2024